SeekingAlpha · Mar 6, 2026
RC
NASDAQ · RCKT
Rocket Pharmaceuticals, Inc.
Healthcare · Biotechnology
$3.41
Down-$0.02 (-0.58%)
Updated Sep 16, 2026, 11:12 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 372.83M
- P/E ratio
- -1.6
- Dividend yield
- 0.00%
- 52-week range
- $2.53 – $5.45
- Volume
- 3.66M
- Avg. volume
- 2.37M
Price performance
RCKT price history
1M range · 20 trading sessions · Daily adjusted prices
RCKT closed at $3.41 after 20 trading sessions, up 2.10% for the selected period.
- Last close
- $3.41
- Period change
- +2.10%
- Period low
- $3.34
- Period high
- $3.86
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.65 | $3.685 | $3.21 | $3.41 | 3.66M |
| Sep 14, 2026 | $3.29 | $3.475 | $3.29 | $3.43 | 1.29M |
| Sep 11, 2026 | $3.52 | $3.52 | $3.25 | $3.35 | 1.66M |
| Sep 10, 2026 | $3.62 | $3.63 | $3.44 | $3.48 | 1.19M |
| Sep 9, 2026 | $3.67 | $3.755 | $3.62 | $3.63 | 871.43K |
| Sep 8, 2026 | $3.78 | $3.7819 | $3.68 | $3.71 | 754.69K |
| Sep 4, 2026 | $3.75 | $3.88 | $3.73 | $3.86 | 888.54K |
| Sep 3, 2026 | $3.90 | $3.915 | $3.69 | $3.79 | 1.07M |
| Sep 2, 2026 | $3.71 | $3.955 | $3.71 | $3.86 | 1.16M |
| Sep 1, 2026 | $3.72 | $3.805 | $3.674 | $3.73 | 948.75K |
| Aug 31, 2026 | $3.77 | $3.80 | $3.6361 | $3.72 | 1.6M |
| Aug 28, 2026 | $3.61 | $3.9899 | $3.53 | $3.86 | 3.45M |
| Aug 27, 2026 | $3.63 | $3.76 | $3.59 | $3.62 | 1.26M |
| Aug 26, 2026 | $3.73 | $3.73 | $3.58 | $3.66 | 1.12M |
| Aug 25, 2026 | $3.54 | $3.81 | $3.5359 | $3.78 | 2.2M |
| Aug 24, 2026 | $3.53 | $3.55 | $3.375 | $3.53 | 913.3K |
| Aug 21, 2026 | $3.52 | $3.605 | $3.48 | $3.51 | 939.79K |
| Aug 20, 2026 | $3.60 | $3.659 | $3.43 | $3.48 | 1.11M |
| Aug 19, 2026 | $3.41 | $3.66 | $3.40 | $3.65 | 1.44M |
| Aug 18, 2026 | $3.33 | $3.421 | $3.27 | $3.34 | 1.09M |
Latest RCKT news
The latest Smart Investors Daily articles mentioning RCKT.
Stock researchCompany · Overview
RCKT research
Overview
Company profile and research snapshot.
Company profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Needham | Buy | — |
| Sep 15, 2026 | Chardan Capital | Buy | — |
| Sep 1, 2026 | Chardan Capital | Buy | — |
| Aug 11, 2026 | Wedbush | Outperform | — |
| May 11, 2026 | Chardan Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 2, 2026
Goldman Sachs Maintains Sell on Rocket Pharmaceuticals, Raises Price Target to $3
Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sell and raises the price target from $2 to $3.
Benzinga · Feb 27, 2026
Rocket Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS results. Also, Cantor Fitzgerald raised its price target on the stock from $8 to $10.
Benzinga · Feb 27, 2026
Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $10
Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target from $8 to $10.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
